First Cannabis Revenues in Sight for CPH

Nov 7, 2016

The medicinal cannabis industry, whilst attracting a lot of publicity, is still in its early stages as a new niche with very few current or even experienced market participants. Even the big pharma companies have so far been apprehensive towards taking significant stakes in medicinal cannabis, and have preferred to wait out the legislative rigmarole making headlines in the US, Europe and Australia.

Read Article

NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks

Oct 26, 2016

Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.

Read Article

Positive Phase II Results: DXB on Track to Find Kidney Disease Solution

Oct 10, 2016

There could be a light at the end of the tunnel for chronic kidney disease sufferers, suffering from a rare form of the disease known as focal segmental glomerulosclerosis (FSGS). In fact several multi-million dollar companies in the space are dedicated to delivering life changing therapies to people living with chronic kidney disease with significant unmet medical needs.

Read Article

MXC Expecting Imminent Medical Cannabis Revenue Deals

Oct 6, 2016

As Australia prepares for the legalisation of medicinal marijuana in November – following bipartisan support at a Federal level and a formal decision by the Therapeutic Goods Administration – the future is looking encouraging for medical cannabis company MGC Pharmaceuticals (ASX:MXC).

Read Article

CDY Sales Up 72%: $100M Revenue Targets in Place

Sep 14, 2016

Calendar year 2016 will go down as a dynamic period of growth in the life of Cellmid (ASX: CDY), a revenue generating life sciences company with lead programs in multiple disease indications and a consumer health business which has just come into its own in the last 12 months.

Read Article
Be alerted as soon as an article is released - Join our mailing list (FREE)
  • close

Are you a sophisticated investor?